MedTrace Logo

Diaplex and Glycemic Control

NCT07711587 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-17

No results posted yet for this study

Summary

The goal of this 16-week double-blind, placebo-controlled pilot study is to determine whether daily Diaplex supplementation improves insulin sensitivity and glycemic control in adults with elevated blood glucose levels, while generating high-quality preliminary data on metabolic effects, glycemic patterns, and safety to inform future trials

Conditions

  • Insulin Sensitivity
  • Healthy Adult

Interventions

DIETARY_SUPPLEMENT

Diaplex

Standard Process Diaplex product

DIETARY_SUPPLEMENT

Placebo

Placebo with no chormium ingredients

Sponsors & Collaborators

  • Standard Process Inc.

    lead INDUSTRY

Principal Investigators

  • Shirin Pourafshar, PhD · Clinical Study Manager

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-10-30
Completion
2027-12-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07711587 on ClinicalTrials.gov